Differences in baseline characteristics between patients prescribed sitagliptin versus exenatide based on a US electronic medical record database.

@article{Zhang2010DifferencesIB,
  title={Differences in baseline characteristics between patients prescribed sitagliptin versus exenatide based on a US electronic medical record database.},
  author={Qiaoyi Zhang and Srini Rajagopalan and Panagiotis Mavros and Samuel S Engel and Michael J Davies and Donald Yin and Larry Radican},
  journal={Advances in therapy},
  year={2010},
  volume={27 4},
  pages={223-32}
}
INTRODUCTION Sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, and exenatide, an injectable glucagon-like peptide-1 receptor agonist, are incretin-based therapies for the treatment of type 2 diabetes. This study examined differences in baseline characteristics between patients with type 2 diabetes initiating sitagliptin vs. exenatide treatment in… CONTINUE READING